Veuillez noter que la page demandée n’est pas disponible dans la langue par défaut sélectionnée. Vous utilisez notre plateforme dans une autre langue maintenant.
This statistic presents the forecast of Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) of Johnson & Johnson for 2020 and 2021. The EBITDA of Johnson & Johnson was expected to amount to approximately 33.1 billion U.S. dollars in 2021.
Forecast of EBITDA of Johnson & Johnson in 2020 and 2021 (in million U.S. dollars)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Johnson & Johnson
Global positioning
6
- Premium Statistic Pharmaceutical market: worldwide revenue 2001-2023
- Premium Statistic Top 50 pharmaceutical companies - Rx sales and R&D spending 2022
- Premium Statistic Top 10 biotech and pharmaceutical companies based on market cap 2024
- Basic Statistic Sales forecast of top pharmaceutical companies worldwide 2028
- Basic Statistic AI readiness of big pharma companies 2023
- Basic Statistic Leading biotech accelerators and incubators worldwide 2022
Key company data
5
- Premium Statistic Johnson & Johnson's total sales 2005-2023
- Premium Statistic Sales of Johnson & Johnson 2006-2023 by region
- Basic Statistic Johnson & Johnson's net earnings 2005-2023
- Basic Statistic Johnson & Johnson's expenditure on research and development 2005-2023
- Premium Statistic Johnson & Johnson's number of employees 2004-2023
Segments
4
- Premium Statistic Sales of Johnson & Johnson worldwide 2011-2023, by segment
- Premium Statistic Sales of Johnson & Johnson's pharmaceutical products 2021-2023
- Premium Statistic Sales of Johnson & Johnson's medtech segment by franchise 2021-2023
- Basic Statistic Sales of Johnson & Johnson's consumer healthcare segment by franchise 2014-2022
Competitors
7
- Premium Statistic Top global pharmaceutical companies based on pharma revenue 2022
- Premium Statistic Roche Group's total sales 2006-2023
- Premium Statistic Pfizer's total revenue 2006-2023
- Premium Statistic Novartis' revenue 2007-2023
- Premium Statistic Medical technology - top companies based on revenue 2022
- Premium Statistic Medtronic's total revenue 2006-2023
- Premium Statistic Global revenue of Philips 2009-2023
Research and Development
5
- Premium Statistic Total global pharmaceutical R&D spending 2014-2028
- Premium Statistic Top pharma companies worldwide 2024, by size of R&D pipeline
- Basic Statistic Top pharma companies worldwide by number of originated drugs 2024
- Premium Statistic Johnson & Johnson's R&D expenditure as a percent of sales 2005-2023
- Premium Statistic Ongoing R&D projects targeting bacteria as of 2021, by pharmaceutical company
Further related statistics
10
- Value of global financial assets 1990-2013
- Structure of investment portfolio of Allianz Group 2014-2023
- Rio Tinto's net income 2005-2023
- Walgreens operating income in the U.S. 2005-2023
- Value of assets managed by global ETFs 2010-2017, by region
- Number of mutual funds worldwide 2011-2014, by country
- Senior chief financial officer salary per annum in Switzerland 2023
- BayWa's revenue by segment 2010-2022
- Return on average common shareholder equity at Goldman Sachs 2009-2023
- Syngenta's sales in the crop protection segment worldwide 2013-2022
Further Content: You might find this interesting as well
Statistics
- Value of global financial assets 1990-2013
- Structure of investment portfolio of Allianz Group 2014-2023
- Rio Tinto's net income 2005-2023
- Walgreens operating income in the U.S. 2005-2023
- Value of assets managed by global ETFs 2010-2017, by region
- Number of mutual funds worldwide 2011-2014, by country
- Senior chief financial officer salary per annum in Switzerland 2023
- BayWa's revenue by segment 2010-2022
- Return on average common shareholder equity at Goldman Sachs 2009-2023
- Syngenta's sales in the crop protection segment worldwide 2013-2022
Quandl. (October 19, 2021). Forecast of EBITDA of Johnson & Johnson in 2020 and 2021 (in million U.S. dollars) [Graph]. In Statista. Retrieved June 10, 2024, from https://www.statista.com/statistics/633322/forecast-of-ebitda-of-johnson-and-johnson/
Quandl. "Forecast of EBITDA of Johnson & Johnson in 2020 and 2021 (in million U.S. dollars)." Chart. October 19, 2021. Statista. Accessed June 10, 2024. https://www.statista.com/statistics/633322/forecast-of-ebitda-of-johnson-and-johnson/
Quandl. (2021). Forecast of EBITDA of Johnson & Johnson in 2020 and 2021 (in million U.S. dollars). Statista. Statista Inc.. Accessed: June 10, 2024. https://www.statista.com/statistics/633322/forecast-of-ebitda-of-johnson-and-johnson/
Quandl. "Forecast of Ebitda of Johnson & Johnson in 2020 and 2021 (in Million U.S. Dollars)." Statista, Statista Inc., 19 Oct 2021, https://www.statista.com/statistics/633322/forecast-of-ebitda-of-johnson-and-johnson/
Quandl, Forecast of EBITDA of Johnson & Johnson in 2020 and 2021 (in million U.S. dollars) Statista, https://www.statista.com/statistics/633322/forecast-of-ebitda-of-johnson-and-johnson/ (last visited June 10, 2024)
Forecast of EBITDA of Johnson & Johnson in 2020 and 2021 (in million U.S. dollars) [Graph], Quandl, October 19, 2021. [Online]. Available: https://www.statista.com/statistics/633322/forecast-of-ebitda-of-johnson-and-johnson/